Azenta vs Neogenomics
Neogenomics is the larger business, with $727m of revenue in fiscal 2025 against $594m for Azenta (1.2 times as much). Neogenomics grew faster (10.1% against 3.6%). Azenta kept more of each dollar of sales as profit: a net margin of -9.4% against -14.9%.
| Latest fiscal year | AzentaAZTA, 2025 | NeogenomicsNEO, 2025 |
|---|---|---|
| Revenue | $594m | $727m |
| Revenue growth | 3.6% | 10.1% |
| Net income | −$55.8m | −$108m |
| Operating margin | -4.5% | — |
| Net margin | -9.4% | -14.9% |
| Return on equity | -3.2% | -12.4% |
| Free cash flow | $38.3m | −$21.8m |
| Cash | $280m | $160m |
| Total debt | $0 | $345m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | — |
| Employees | 3,000 | 2,500 |
| Market value | $1.63bn | $2.20bn |
| Price vs our value range | Above our value range | — |
| Moat score | 46 (Moderate) | 34 (Weak) |
| Insider trades, 12 months | 2 buys, 0 sales | 0 buys, 0 sales |